{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:08:24Z","timestamp":1792796904207,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clinthera.2021.06.011","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T06:52:59Z","timestamp":1628405579000},"page":"1300-1319.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States"],"prefix":"10.1016","volume":"43","author":[{"given":"Cynthia Z.","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Bollu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2021.06.011_bib0001","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0002","unstructured":"World Health Organization. Diffuse large B-cell lymphoma. Accessed on: April 4, 2020. Available from: http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/applications\/DiffuseLargeBCellLymphoma.pdf."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0003","unstructured":"National Cancer Insitute: Surveillance Epidemiology and End Results Program (SEER). Cancer Stat Facts: NHL-Diffuse Large B-Cell Lymphoma (DLBCL). Accessed on: March 25, 2021. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Br J Haematol"},{"issue":"Supplement_5","key":"10.1016\/j.clinthera.2021.06.011_bib0006","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0008","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY. 12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0010","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0011","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","article-title":"Immunogenicity of chimeric antigen receptor T-cell therapeutics","volume":"33","author":"Gorovits","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0012","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","article-title":"Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia","volume":"53","author":"Liu","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0013","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: KYMRIAH (tisagenlecleucel). Accessed on: October 28, 2019. Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-KYMRIAH.pdf."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0014","unstructured":"United States Food and Drug Administration (FDA). FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. Accessed on: October 22, 2019. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2021.06.011_bib0016","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2019-129107","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the JULIET trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2021.06.011_bib0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the JULIET trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0018","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2021.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2021.06.011_bib0020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0021","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0022","unstructured":"United States Food and Drug Administration (FDA). FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. Accessed on: October 16, 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0023","unstructured":"United States Food and Drug Administration (FDA). FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Accessed on: October 16, 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0024","unstructured":"ASH Clinical News. Polatuzumab vedotin-piiq receives FDA approval for DLBCL. Accessed on: October 16, 2020. Available from: https:\/\/www.ashclinicalnews.org\/news\/latest-and-greatest\/fda-approves-polatuzumab-vedotin-piiq-treatment-dlbcl\/."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0025","unstructured":"United States Food and Drug Administration (FDA). Highlights of prescribing information: BREYANZI (lisocabtagene maraleucel). Accessed on: March 2, 2021. Available from: https:\/\/www.fda.gov\/media\/145711\/download."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0026","first-page":"1","article-title":"A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible?","author":"Zhang","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0027","unstructured":"Woods B., Sideris E., Palmer S., Latimer N., Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. (Technical Support Document). NICE Decision Support Unit. Accessed on: March 25, 2021. Available from: http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0028","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0029","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-009-0941-9","article-title":"Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma","volume":"64","author":"Corazzelli","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0030","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the JULIET trial","author":"Westin","year":"2019","journal-title":"Presented at The American Society of Hematology Annual Meeting on December 7-10, 2019 in Orlando, FL, US."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0031","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0032","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-11-2859","article-title":"Cure models as a useful statistical tool for analyzing survival","volume":"18","author":"Othus","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0033","unstructured":"System CfDCaP-NVS. United States life tables, 2017 (volume 67, number 7). Accessed on: March 31, 2021. Available from: https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_07-508.pdf."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0034","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0035","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","article-title":"Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease","volume":"24","author":"Guadagnolo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0036","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1080\/10428194.2017.1390230","article-title":"Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0037","unstructured":"Institute for Clinical and Economic Review (ICER). ICER Final Evidence Report (2018): Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value. Accessed on: October 30, 2019. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/07\/ICER_CAR_T_Final_Evidence_Report_032318.pdf."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0038","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","article-title":"Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease","volume":"24","author":"Guadagnolo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0039","unstructured":"IBM. Micromedex RED BOOK. Accessed on: August 20, 2020. Available from: www.micromedexsolutions.com."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0040","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule. Accessed on: August 28, 2020. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/overview.aspx."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0041","unstructured":"Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. Accessed on: August 30, 2020. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0042","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2018.1459613","article-title":"Costs of relapsed diffuse large B-cell lymphoma among Medicare patients","volume":"59","author":"Huntington","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0043","series-title":"Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with tisagenlecleucel","author":"Andreadis","year":"2019"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0044","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of CTL019 in adult DLBCL patients (JULIET). Accessed on: March 25, 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02445248."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0045","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct costs associated with relapsed diffuse large B-cell lymphoma therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0046","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) Inpatient database. Accessed on: June 23, 2019. Available from: https:\/\/www.ahrq.gov\/data\/hcup\/index.html."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0047","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0048","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jcyt.2015.09.002","article-title":"Hematopoietic progenitor cell mobilization with \u201cjust-in-time\u201d plerixafor approach is a cost-effective alternative to routine plerixafor use","volume":"17","author":"Veltri","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0049","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.bmt.1701945","article-title":"Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation","volume":"24","author":"Bennett","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428194.2017.1375100","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"59","author":"Maziarz","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0051","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7) for B-Cell Lymphomas V.7.2019\u2014December 18, 2019. \u00a9 National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0052","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0053","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JOP.2011.000469","article-title":"Health care costs for patients with cancer at the end of life","volume":"8","author":"Chastek","year":"2012","journal-title":"J Oncol Prac"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0054","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0055","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2021.06.011_bib0057","unstructured":"Centers for Medicare & Medicaid Services (CMS). CMS Outpatient Prospective Payment System (PPS). Accessed on: June 23, 2019. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/HospitalOutpatientPPS\/Hospital-Outpatient-Regulations-and-Notices-Items\/CMS-1695-FC.html."},{"key":"10.1016\/j.clinthera.2021.06.011_bib0058","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CCM.0b013e3181b090d0","article-title":"Critical care medicine in the United States 2000\u20132005: an analysis of bed numbers, occupancy rates, payer mix, and costs","volume":"38","author":"Halpern","year":"2010","journal-title":"Crit Care Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:35Z","timestamp":1758963275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0149291821002423"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}